Trinity Biotech (NASDAQ:TRIB) Downgraded by ValuEngine to Sell

ValuEngine lowered shares of Trinity Biotech (NASDAQ:TRIB) from a hold rating to a sell rating in a research report released on Thursday morning, ValuEngine reports.

Shares of NASDAQ:TRIB traded down $0.06 during trading hours on Thursday, hitting $0.89. 71,091 shares of the company’s stock traded hands, compared to its average volume of 61,775. Trinity Biotech has a 52 week low of $0.89 and a 52 week high of $3.99. The company has a debt-to-equity ratio of 2.09, a quick ratio of 2.07 and a current ratio of 3.36. The company’s fifty day simple moving average is $1.25 and its two-hundred day simple moving average is $2.01.

Trinity Biotech (NASDAQ:TRIB) last posted its quarterly earnings data on Tuesday, August 20th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.26). Trinity Biotech had a negative net margin of 30.92% and a negative return on equity of 8.96%. The business had revenue of $22.50 million for the quarter.

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC raised its position in shares of Trinity Biotech plc (NASDAQ:TRIB) by 33.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,434,110 shares of the company’s stock after buying an additional 355,500 shares during the quarter. Hunter Associates Investment Management LLC owned 5.97% of Trinity Biotech worth $2,366,000 at the end of the most recent quarter. 49.16% of the stock is owned by institutional investors and hedge funds.

About Trinity Biotech

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.

See Also: What is a dividend reinvestment plan?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.